Venous thromboembolism in the medically ill patient: A call to action

International Journal of Clinical Practice

Volumn 59, Issue 5, 2005, Pages 555-561

  Bergmann, J F ^a   Kher, A ^b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b Euthemis   (France)

Author keywords

Heparin; Low molecular weight heparin; Medical patients; Prevention; Venous thromboembolism

Indexed keywords

ARITRIXA; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; ANTICOAGULANT AGENT;

AUTOPSY; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; EMBOLISM PREVENTION; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; META ANALYSIS; MORTALITY; PATIENT MOBILITY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 27144522052     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00529.x     Document Type: Review

References (42)

1. Cohen AT. Discoveries in thrombosis care for medical patients. Semin Thromb Hemost 2002; 28: 13-7.
2. Cohen AT, Alikhan R. Prophylaxis of venous thromboembolism in medical patients. Curr Opin Pulm Med 2001; 7: 332-7.
3. Thromboembolic Risk Factors (THRiFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-74.
4. Cohen AT, Edmonson RA, Phillips MJ, Ward VP, Kakkar VV. The changing pattern of venous thromboembolic disease. Haemostasis 1996; 26: 65-71.
5. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10: 448-50.
6. Oger E, Bressollette L, Nonent M et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost 2002; 88: 592-7.
7. Geerts W, Cook D, Selby R, Etchells E. Venous thromboembolism and its prevention in critical care. J Crit Care 2002; 17: 95-104.
8. Mismetti P, Laporte-Simitsidis S, Tardy B et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-9.
9. Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003; 8: 381-8.
10. Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1992; 151: 933-8.
11. Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994; 154: 861-6.
12. Oger E. Incidence of venous thromboembolism: a community-based study in western France. Thromb Haemost 2000; 83: 657-60.
13. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism -a population-based case-control study. Arch Intern Med 2000; 160: 809-15.
14. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: The Sirius study. Arch Intern Med 2000; 160: 3415-20.
15. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-9.
16. Samama MM, Cohen AT, Darmon J-Y et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793-800.
17. Bergmann JF, Mouly S. Thromboprophylaxis in medical patients, focus on France. Semin Thromb Hemost 2002; 28 (Suppl. 3): 51-5.
18. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 203-5.
19. Goldhaber SZ, Hennekens CH, Evans DA, Newton EC, Godleski JJ. Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med 1982; 73: 822-6.
20. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991; 302: 709-11.
21. Pineda LA, Hathwar VS, Grant BJ. Clinical suspicion of fatal pulmonary embolism. Chest 2001; 120: 791-5.
22. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 2001; 120: 1964-71.
23. Jacobs LG. Prophylactic anticoagulation for venous thromboembolic disease in geriatric patients. J Am Geriatr Soc 2003; 51: 1472-8.
24. Haas SK. Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost 2002; 28: 577-83.
25. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93: 259-62.
26. Ageno W, Squizzato A, Ambrosini F et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 2002; 87: 746-50.
27. Bosson JL, Labarere J, Sevestre MA et al. Deep vein thrombosis in elderly patients hospitalized in subacute care facilities: a multicenter cross-sectional study of risk factors, prophylaxis, and prevalence. Arch Intern Med 2003; 163: 2613-8.
28. Gatt ME, Paltiel O, Bursztyn M. Is prolonged immobilization a risk factor for symptomatic venous thromboembolism in elderly bedridden patients? Results of a historical-cohort study. Thromb Haemost 2004; 91: 538-43.
29. Collins R, MacMahon S, Flather M et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996; 313: 652-9.
30. Counsell C, Sandercock P. The efficacy and safety of anticoagulant therapy in patients with acute presumed ischaemic stroke: a systematic review of the randomized trials comparing anticoagulants with control. In: The Cochrane Database Library Cochrane Collaboration, Oxford: Update Software 1997.
31. Collins R, Scrimgeour A, Yusuf S, Phil D, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318: 1162-73.
32. Alikhan R, Cohen AT, Combe S et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14: 341-6.
33. Vaitkus PT, Leizorovicz A, Goldhaber SZ. Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vasc Med 2002; 7: 269-73.
34. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998; 129: 1044-9.
35. Bressollette L, Nonent M, Oger E et al. Diagnostic accuracy of compression ultrasonography for the detection of asymptomatic deep venous thrombosis in medical patients - the TADEUS project. Thromb Haemost 2001; 86: 529-33.
36. Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005; 93: 76-9.
37. Cohen AT, Davidson BL, Gallus AS et al. Fondaparinux for the prevention of VTE in acutely ill medical patients. Blood 2003; 102: 15A (Abstract 42).
38. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
39. Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. ACCP 1995 recommendations - prevention of venous thromboembolism. Chest 1995; 108: 312S-34S.
40. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism: Sixth ACCP Consensus conference on antithrombotic therapy. Chest 2001; 119: 132S-75S.
41. Tapson V, Decousus H, Piovella F et al. A multinational observational cohort study in acutely ill medical patients of practices in prevention of venous thromboembolism: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE). Blood 2003; 102: 321A (Abstract 1154).
42. Pini M, Froehlich J, Bergmann J-F et al. Comparison of US and European practices in the prevention of venous thromboembolism in hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE). Blood 2003; 102: 320A (Abstract 1151).